SUCCESS: Radius Health acquired by by Gurnet Point Capital and Patient Square Capital
Get out: a sales based CVR hit
Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.
I don’t care for sales based CVRs, the sales teams always seem to miss these targets but here we have a winner.
On June 23, 2022 the following was released:
“Under the terms of the merger agreement, an entity jointly owned by Gurnet Point and Patient Square will initiate a tender offer to acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a CVR of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during any consecutive 12-month period prior to December 31, 2025.”
Maybe there is hope for my Paratek CVR that Gurnett controls now….
https://substack.com/@contingentvaluerights/p-135918753
All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.